ANO1 and lung carcinoma: As a natural product with no hepatotoxicity or adverse cardiac effects, vitexicarpin holds promise as a valuable pharmacological tool in ANO1 inhibitor research and as a potential therapeutic for CRC and lung cancers, particularly in cases of resistance to existing anticancer drugs.